GNI Group (3G6) Stock Overview
Engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 3G6 from our risk checks.
3G6 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
GNI Group Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥14.30 |
| 52 Week High | JP¥26.00 |
| 52 Week Low | JP¥8.80 |
| Beta | 1.27 |
| 1 Month Change | 13.49% |
| 3 Month Change | 5.15% |
| 1 Year Change | -25.13% |
| 3 Year Change | 73.33% |
| 5 Year Change | -16.37% |
| Change since IPO | 775.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3G6 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.9% | 4.5% | 0.6% |
| 1Y | -25.1% | -9.4% | 10.7% |
Return vs Industry: 3G6 underperformed the German Biotechs industry which returned -8.9% over the past year.
Return vs Market: 3G6 underperformed the German Market which returned 9.9% over the past year.
Price Volatility
| 3G6 volatility | |
|---|---|
| 3G6 Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 13.0% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 3G6 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 3G6's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 867 | Ying Luo | www.gnipharma.com |
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue-associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy.
GNI Group Ltd. Fundamentals Summary
| 3G6 fundamental statistics | |
|---|---|
| Market cap | €814.95m |
| Earnings (TTM) | -€4.49m |
| Revenue (TTM) | €140.80m |
Is 3G6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3G6 income statement (TTM) | |
|---|---|
| Revenue | JP¥25.78b |
| Cost of Revenue | JP¥7.04b |
| Gross Profit | JP¥18.74b |
| Other Expenses | JP¥19.56b |
| Earnings | -JP¥822.34m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 13, 2026
| Earnings per share (EPS) | -14.77 |
| Gross Margin | 72.68% |
| Net Profit Margin | -3.19% |
| Debt/Equity Ratio | 6.9% |
How did 3G6 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/26 00:20 |
| End of Day Share Price | 2026/01/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GNI Group Ltd. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Stephen Barker | Jefferies LLC |
| Yuriko Ishida | Mizuho Securities Co., Ltd. |
| Matthew Pelham Smithers | Pelham Smithers Associates Ltd. |